Literature DB >> 9012394

Effect of left atrial size on recurrence of atrial fibrillation after electrical cardioversion: atrial dimension versus volume.

A S Volgman1, J S Soble, A Neumann, K N Mukhtar, F Iftikhar, A Vallesteros, P R Liebson.   

Abstract

UNLABELLED: There are conflicting reports on the relationship between left atrial dimension (LAD) determined by echo-cardiography and the incidence of atrial fibrillation (AF) recurrence after electrical cardioversion (EC). We hypothesized that left atrial volume (LAV) by echocardiography might better differentiate patients who will have recurrence of AF after EC.
METHODS: Forty-one patients having EC for AF were prospectively studied by echocardiography. LAD was measured by American Society of Echocardiography guidelines as the anterior-posterior dimension in the parasternal view. LAV was measured by Simpson's method using an off-line analysis system and reported as the average of values from the apical four-chamber and two-chamber views.
RESULTS: (Data are mean +/- SEM): Patient follow-up was 15 +/- 10 months. No cutoff value of LAV predicted AF recurrence, but all three patients with LAD greater than 65 mm had AF recurrence. Compared with patients maintaining normal sinus rhythm (NSR) (N = 18), the AF group (N = 23) had a lower percentage of antiarrhythmic drug use, especially type IA agents (p < .02). Patients who stayed in NSR tended to have shorter AF duration before EC (16 +/- 15 v 63 +/- 122 weeks, p = .08) but did not differ in age (53 +/- 27 v 58 +/- 23 years), LAD (51.1 +/- 7.7 v 54.2 +/- 9.4 mm) or LAV (85.1 +/- 24.3 v 95.1 +/- 33.3 mL).
CONCLUSIONS: (1) LAV by echocardiography does not improve identification of patients at risk for recurrence of AF after EC, (2) patients with LAD up to 65 mm may maintain NSR after EC, (3) LAD greater than 65 mm is associated with AF recurrence, and (4) use of antiarrhythmic drugs and the duration of AF before EC may be better predictors of maintenance of NSR than echocardiographic measures of left atrial parameters.

Entities:  

Mesh:

Year:  1996        PMID: 9012394

Source DB:  PubMed          Journal:  Am J Card Imaging        ISSN: 0887-7971


  8 in total

Review 1.  Recent developments in atrial fibrillation.

Authors:  M Bilal Iqbal; Anil K Taneja; Gregory Y H Lip; Marcus Flather
Journal:  BMJ       Date:  2005-01-29

2.  Factors related to the early and late success of direct current cardioversion of chronic nonrheumatic atrial fibrillation: An echocardiographic study.

Authors:  M Szulc; H Gurba; A Kuch-Wocial; P Pruszczyk; Z Miskiewicz; I Chlewicka; J Stanislawska; A Górecki; G Swiecicka; G Opolski; A Torbicki
Journal:  Exp Clin Cardiol       Date:  2001

Review 3.  Role of Echocardiography in the Management and Prognosis of Atrial Fibrillation.

Authors:  David I Silverman; Srilatha R Ayirala; Warren J Manning
Journal:  J Atr Fibrillation       Date:  2012-02-02

4.  Echocardiographic features of patients with paroxysmal atrial fibrillation.

Authors:  Yucel Colkesen; Tayfun Acil; Senol Demircan; Alpay T Sezgin; Bulent Ozin; Haldun Muderrisoglu
Journal:  Int J Cardiovasc Imaging       Date:  2007-06-28       Impact factor: 2.357

5.  Longitudinal tracking of left atrial diameter over the adult life course: Clinical correlates in the community.

Authors:  David D McManus; Vanessa Xanthakis; Lisa M Sullivan; Justin Zachariah; Jayashri Aragam; Martin G Larson; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Circulation       Date:  2010-01-25       Impact factor: 29.690

6.  Cardioversion: What to choose? Etomidate or propofol.

Authors:  Pushkar M Desai; Deepa Kane; Manjula S Sarkar
Journal:  Ann Card Anaesth       Date:  2015 Jul-Sep

7.  Short-term and long-term success of electrical cardioversion in atrial fibrillation in managed care system.

Authors:  Suman S Kuppahally; Elyse Foster; Stanford Shoor; Anthony E Steimle
Journal:  Int Arch Med       Date:  2009-12-12

8.  Prediction of sinus rhythm maintenance following DC-cardioversion of persistent atrial fibrillation - the role of atrial cycle length.

Authors:  Carl J Meurling; Anders Roijer; Johan E P Waktare; Fredrik Holmqvist; Carl J Lindholm; Max P Ingemansson; Jonas Carlson; Martin Stridh; Leif Sörnmo; S Bertil Olsson
Journal:  BMC Cardiovasc Disord       Date:  2006-03-13       Impact factor: 2.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.